Krystal Biotech (NASDAQ:KRYS) Earns Buy Rating from HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $310.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 0.31% from the stock’s previous close.

Several other brokerages have also recently commented on KRYS. Citigroup boosted their price objective on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Evercore reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 5th. Chardan Capital boosted their price objective on shares of Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Wall Street Zen raised shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Wolfe Research began coverage on shares of Krystal Biotech in a research note on Friday, March 27th. They set a “peer perform” rating for the company. Ten equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, Krystal Biotech currently has a consensus rating of “Moderate Buy” and an average price target of $324.11.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS opened at $309.03 on Monday. The company has a 50 day moving average of $277.59 and a 200 day moving average of $261.20. The stock has a market cap of $9.11 billion, a P/E ratio of 41.31 and a beta of 0.53. Krystal Biotech has a 12 month low of $123.03 and a 12 month high of $319.48.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, May 4th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.45 by $0.38. The company had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. On average, equities analysts forecast that Krystal Biotech will post 7.83 earnings per share for the current fiscal year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $263.21, for a total transaction of $6,580,250.00. Following the completion of the sale, the insider directly owned 1,403,155 shares in the company, valued at $369,324,427.55. The trade was a 1.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP John Charles Thomas sold 642 shares of Krystal Biotech stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total transaction of $193,903.26. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds have recently bought and sold shares of the stock. UMB Bank n.a. lifted its position in Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after purchasing an additional 37 shares during the last quarter. Optimize Financial Inc lifted its holdings in shares of Krystal Biotech by 1.4% in the 4th quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock worth $704,000 after acquiring an additional 40 shares during the last quarter. Perigon Wealth Management LLC lifted its holdings in shares of Krystal Biotech by 0.5% in the 4th quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock worth $2,211,000 after acquiring an additional 41 shares during the last quarter. Regal Investment Advisors LLC lifted its holdings in shares of Krystal Biotech by 1.0% in the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock worth $1,075,000 after acquiring an additional 44 shares during the last quarter. Finally, Torray Investment Partners LLC lifted its holdings in shares of Krystal Biotech by 0.4% in the 1st quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock worth $3,108,000 after acquiring an additional 47 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.